Ainos Announces Positive Results from Preclinical Studies of Its Low-dose Oral Interferon Formulation Against COVID-19

Hamsters Receiving Ainos’ VELDONA Formulation Demonstrate Protection from COVID-19 Based on Prespecified Indicators of Clinical Outcomes SAN DIEGO, June 27, 2022 /PRNewswire/ — Ainos, Inc. (OTC PINK: AIMD) (“Ainos”, or the “Company”), a diversified medtech company focused on the…

Click here to view original post